dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Kohl, Yvonne |
dc.contributor.author | Biehl, Margit |
dc.contributor.author | Spring, Sarah |
dc.contributor.author | Hesler, Michelle |
dc.contributor.author | Ogourtsov, Vladimir |
dc.contributor.author | Todorovic, Miomir |
dc.contributor.author | Franco Puntes, Victor |
dc.date.accessioned | 2021-07-12T11:31:42Z |
dc.date.available | 2021-07-12T11:31:42Z |
dc.date.issued | 2021-04-15 |
dc.identifier.citation | Kohl Y, Biehl M, Spring S, Hesler M, Ogourtsov V, Todorovic M, et al. Microfluidic In Vitro Platform for (Nano)Safety and (Nano)Drug Efficiency Screening. Small. 2021 Apr;17(15):e2006012. |
dc.identifier.issn | 1613-6829 |
dc.identifier.uri | https://hdl.handle.net/11351/6150 |
dc.description | (Nano)safety; Drug efficiency; Microfluidic platform |
dc.description.abstract | Microfluidic technology is a valuable tool for realizing more in vitro models capturing cellular and organ level responses for rapid and animal-free risk assessment of new chemicals and drugs. Microfluidic cell-based devices allow high-throughput screening and flexible automation while lowering costs and reagent consumption due to their miniaturization. There is a growing need for faster and animal-free approaches for drug development and safety assessment of chemicals (Registration, Evaluation, Authorisation and Restriction of Chemical Substances, REACH). The work presented describes a microfluidic platform for in vivo-like in vitro cell cultivation. It is equipped with a wafer-based silicon chip including integrated electrodes and a microcavity. A proof-of-concept using different relevant cell models shows its suitability for label-free assessment of cytotoxic effects. A miniaturized microscope within each module monitors cell morphology and proliferation. Electrodes integrated in the microfluidic channels allow the noninvasive monitoring of barrier integrity followed by a label-free assessment of cytotoxic effects. Each microfluidic cell cultivation module can be operated individually or be interconnected in a flexible way. The interconnection of the different modules aims at simulation of the whole-body exposure and response and can contribute to the replacement of animal testing in risk assessment studies in compliance with the 3Rs to replace, reduce, and refine animal experiments. |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | Small;17(15) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Microfluídica |
dc.subject | Medicaments - Assaigs clínics |
dc.subject.mesh | Microfluidic Analytical Techniques |
dc.subject.mesh | Drug Evaluation, Preclinical |
dc.subject.mesh | /instrumentation |
dc.title | Microfluidic In Vitro Platform for (Nano)Safety and (Nano)Drug Efficiency Screening |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1002/smll.202006012 |
dc.subject.decs | técnicas analíticas microfluídicas |
dc.subject.decs | evaluación preclínica de medicamentos |
dc.subject.decs | /instrumentación |
dc.relation.publishversion | https://onlinelibrary.wiley.com/doi/10.1002/smll.202006012 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Kohl Y, Biehl M, Spring S, Hesler M] Fraunhofer Institute for Biomedical Engineering IBMT, Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., Joseph-von-Fraunhofer-Weg 1, Sulzbach, Germany. [Ogourtsov V, Todorovic M] Tyndall National Institute, University College Cork, Dyke Parade, Cork, Ireland. [Puntes V] Institut Català de Nanociència i Nanotecnologia (ICN2), CSIC and BIST, Campus UAB, Bellaterra, Barcelona, Spain. Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain |
dc.identifier.pmid | 33458959 |
dc.identifier.wos | 000608216200001 |
dc.relation.projectid | info:eu-repo/grantAgreement/EC/H2020/685817 |
dc.relation.projectid | info:eu-repo/grantAgreement/EC/H2020/857381 |
dc.relation.projectid | info:eu-repo/grantAgreement/EC/H2020/271075 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/SEV-2013-0295-17-3 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |